Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Juno Therapeutics, A Subsidiary Of Celgene

Clinical trials sponsored by Juno Therapeutics, A Subsidiary Of Celgene, explained in plain language.

Now part of Bristol-Myers Squibb Company BMY NYSE

A biotech developing CAR-T cell therapies, now part of Bristol-Myers Squibb.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Immune cell therapy takes on tough blood cancers

Disease control Ongoing

This study tests a treatment called JCAR017, a type of CAR T-cell therapy, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modi…

Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control

Last updated Jul 08, 2026 00:00 UTC